Know your enemy
Knowing the exact extent of the cancer, defining its evolutive character and, above all, having a precise knowledge of its biological characteristics, make it possible to adapt a treatment and, in the case of a well defined faulty molecule, choose targeted treatments.
France has set up an ambitious and internationally renowned programme for the biological characterisation of cancers. INCa biological platforms have been developed throughout France to make this characterisation of all cancers possible for the entire socially insured population. Equally, clinical studies, called AcSé, are taking place in collaboration with the pharmaceutical industry, to test the efficacy of targeted treatment, depending, not on the original organ but on the existence, or not, of a molecular target.
For those who do not benefit from a social health insurance, we propose molecular characterisations carried out by private American or European laboratories. Targeted treatments can also be proposed when biologically justified.
A very productive enthusiasm for research into circulating cancerous cells (also known as circulating tumour cells or CTC cells) and for circulating DNA, enables an improved diagnosis of a cancer and its response to treatments (monitoring of the quantity of CTC or the level of circulating DNA). In some situations, it can make it possible to determine whether recourse to targeted treatments is possible.